Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies

Table 1 Characteristics of anti-HIV bNAbs

Env site	Antibody designation	Neutralization breadth, %	Neutralization potency, μg/ml	Length of CDR H3, a.a.	Somatic mutations %	Year of generation
CD4bs	b12^a	35–75	2.82	18	17.3	1991
	HJ16	36	8.01	21	36.7	2010
	VRC01	88–93	0.09	14	38.8	2010
	VRC02	90–91	0.13	14	34.9	2010
	VRC03	51–59	0.08	16	34.9	2010
	PGV04	77–88	0.14	16	38.2	2011
	CH31	84–91	0.02	15	31.9	2011
	CH33	90	0.24	15	31.9	2011
	NIH45-46	84–86	0.08	18	44	2011
	3BNC117	86–92	0.06	12	36.9	2011
	12A12	92–96	0.07	15	34	2011
	VRC23	65–80	0.58			2013
V1/V2 loop	PG9	77–83	0.08	30	15.4	2009
	PG16	73–79	0.02	30	16.8	2009
	PG145	78	0.29	33	22.8	2011
	CH01	46	3.75	24	23.3	2011
V1/V2 loop	2G12^a	28–39	1.45	16	33.6	1994
	PGT121	70	0.03	26	21.2	2011
	PGT128	72	0.02	21	27.9	2011
CD4i/V3	3BC176	64	12.8	19	29.4	2012
gp41 MPER	2F5^a	55–67	1.44	24	15.2	1992
	4E10^a	85–100	1.62	20	15.6	1994
	Z13	35	40	19	21	2001
	10E8	98–99	0.25	22	22.1	2012
gp120/gp41	PGT151-155	64–66	0.008–0.012	28		2014
Interface	Interface	67	0.87	9		2011

ISSN: 1742-6405